A Survey on the Under-treatment of hypercholeSterolemia (EPHESUS Trial) (EPHESUS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02608645|
Recruitment Status : Unknown
Verified November 2015 by Murat Biteker, Muğla Sıtkı Koçman University.
Recruitment status was: Not yet recruiting
First Posted : November 20, 2015
Last Update Posted : November 20, 2015
|Condition or disease|
In the majority of patients treated with lipid lowering agents are not under control in accordance with the lipids manual. In this study, within the secondary prevention group patients ( diabetes mellitus, coronary artery disease, peripheral artery disease, who have had events atherosclerotic cerebrovascular ) , statin use requirement , patients compliance and reaching target LDL-cholesterol levels (according to European guidelines ) will be evaluated.
The investigators' aim is to determine the role of education and knowledge in reaching target LDL cholesterol levels in these patients. İn addition , the investigators want to emphasize in high-risk patients who are receiving or not receiving cholesterol-lowering treatment what is their target values , (LDL < 100 mg / dL and high -risk patients with LDL < 70 mg / dL in very high-risk patients ) and to determine what is the rate of patients and to the importance of reaching their target cholesterol levels. İn addition ,to evaluate the patients habits of the using statin dose .After screening , physician treatment decisions and reasons will be documented.
|Study Type :||Observational|
|Estimated Enrollment :||6000 participants|
|Official Title:||Evaluation of Perceptions, Knowledge and Compliance With tHE Guidelines for Secondary Prevention in Real Life Practice: A Survey on the Under-treatment of hypercholeSterolemia (EPHESUS Trial)|
|Study Start Date :||November 2015|
|Estimated Primary Completion Date :||September 2016|
|Estimated Study Completion Date :||September 2016|
- The number of patients with secondary prevention group receiving appropriate lipid lowering therapy [ Time Frame: 2 months ]